Navigation Links
No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
Date:9/21/2012

SACRAMENTO, Calif., Sept. 21, 2012 /PRNewswire/ -- According to new reports in the New York Times, BBC, Reuters and other publications, the authors of the highly controversial French study of rats and biotech foods forced reporters to sign non-disclosure agreements prohibiting journalists from validating the report's findings with independent scientists. Clearly, its authors were concerned that the now-debunked study would wilt under scientific scrutiny, which is exactly what has happened now that the report has been reviewed by independent scientific experts.

According to the BBC:

"In a move regarded as unusual by the media, the French research group refused to provide copies of the journal paper to reporters in advance of its publication, unless they signed non-disclosure agreements. The NDAs would have prevented the journalists from approaching third-party researchers for comment."

The New York Time's Dot Earth blog was even more blunt:

"I have to place it in a big bin of suspect studies "done by people out to prove something rather than investigate something," as the evolutionary biologist Michael Eisen said in a late update to my previous post on this work."

The Yes on Prop 37 campaign was coordinating with the French authors from the very beginning. In fact, within a few hours of the study release, Yes on 37 issued a media advisory announcing a press conference with the study's authors.

"It is clear that this so-called study is nothing more than a propaganda piece intended to create false fear and misinformation to help support the flawed Prop 37 campaign," said No on 37 campaign spokesperson Kathy Fairbanks. "After just a few hours of scrutiny, respected scientists and medical reviewers thoroughly discredited the study, its methodology and the authors.  Yes on 37 can't sell their flawed measure based on the facts, so they're forced to result to cheap tricks and junk science."

Paid for by No on 37: Coalition Against the Deceptive Food Labeling Scheme, sponsored by Farmers, Food Producers, and Grocers.  Major funding by Monsanto Company, E.I. DuPont de Nemours & Co., Grocery Manufacturers Association (GMA) and more than 40 food company members.  For a full list of donors visit www.NoProp37.com/donors. - 1-800-331-0850 - www.NoProp37.com

About Prop. 37
Proposition 37 would ban the sale of tens of thousands of perfectly-safe, common grocery products only in California unless they are specially repackaged, relabeled or remade with higher cost ingredients. Prop 37 is a deceptive, deeply flawed food labeling scheme that would add more government bureaucracy and taxpayer costs, create new frivolous lawsuits, and increase food costs by billions — without providing any health or safety benefits. That's why Prop 37 is opposed by a broad coalition of family farmers, scientists, doctors, business, labor, taxpayers and consumers.


'/>"/>
SOURCE No on Prop. 37
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug
4. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
5. Science study shows promiscuous enzymes still prevalent in metabolism
6. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
9. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
10. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
11. Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
(Date:10/9/2017)... Texas (PRWEB) , ... October ... ... study published on October 5, 2017, in the medical journal, Epilepsia, Brain ... with the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):